CAU
IDYA icon

Caxton Associates (UK)’s IDEAYA Biosciences IDYA Stock Holding History

Caxton Associates (UK)’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,070
Closed -$210K – 889
2025
Q4 		$210K Buy
+6,070
New +$194K ﹤0.01% 703

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Caxton Associates (UK)'s IDYA Position: Q1 2026 in Review

Caxton Associates (UK) sold out of IDEAYA Biosciences (IDYA) in Q1 2026, closing a stake of 6,070 shares — an estimated $210K sold.

Caxton Associates (UK) first reported a position in IDYA in Q4 2025 and held it in 1 quarter. The position peaked at $210K in Q4 2025. 254 funds tracked by Wall St. Rank hold IDYA as of Q1 2026.

  • Caxton Associates (UK) reported no remaining IDEAYA Biosciences position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 6,070 IDEAYA Biosciences shares in Q1 2026, an estimated $210K.
  • Caxton Associates (UK) first reported a position in IDEAYA Biosciences in Q4 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s IDEAYA Biosciences position peaked at $210K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.